bluebird bio Inc (BLUE), Iqvia Holdings Inc (IQV): Four Biotech Stocks to Buy Now
Healthcare sector has proven itself to be one of the most resilient sectors of the US economy.
Celgene Corp (CELG)
Market is closed
News
- First
- << Previous
- 11 - 20
- Next >>
Market Movers Today: Etsy Inc (ETSY), Frontier Communications Corp (FTR), Stratasys Ltd (SSYS), PHH Corporation (PHH), and More
Etsy’s stock price jumped as much as 24% in midday trading on Wednesday, and has now more than doubled from a year ago, thanks to Silverman’s turnaround strategy that got the company out of Amazon...
Billionaire Fund Managers Are Bullish On These Biotech Stocks
The biotech sector is well known for its M&A activity, but billionaire fund managers don’t seem to be attracted by the frenzy.
Celgene Corporation (CELG): Here’s What Polen Capital Thinks About It
Florida-based Polen Capital sees value in Celgene Corporation (NASDAQ:CELG), which struggled during the past year.
Celgene Corporation (CELG) Offers Compelling Growth Opportunity: Wedgewood
Missouri-based investment firm Wedgewood Partners loves Celgene Corporation (NASDAQ:CELG), an $81-billion global biopharmaceutical company whose shares lost nearly 10% of their value in 2017.
Netflix, Inc. (NFLX), General Electric Company (GE): Mott Capital Management's Top Winners and Losers of 2017
Mott Capital Management is a thematic growth fund that was founded in 2014 by Michael J. Kramer. Mr.
13D Filing: Celgene Corp /de/ and Alliqua Biomedical Inc. (NASDAQ:ALQA)
Director of the Centre for Accelerating Medical Innovations; Chairman of the Health Innovation Network of South London, UK; Chairman of International Health Partners; Chairman of Precision Medicine Catapult...
Why President Trump Wants To Transform The FDA - And What It Could Mean For Biotech Stocks
A few weeks ago, President Donald Trump met with a series of biotech CEOs to discuss a historically major pain point for the industry: cutting the FDA drug approval process "at a level no one has ever...
Celgene Corporation (CELG) To Acquire Autoimmune Firm Delinia For $775 Million
Five months ago, Delinia was just a fledgling autoimmune startup with just four full-time staff.
Celgene Corporation (CELG) Eyes Expansion In 2017
Celgene Corporation (NASDAQ:CELG) announced today its 2017 GAAP earnings per share of $5.85–$6.21.
- First
- << Previous
- 11 - 20
- Next >>
Billionaire Hedge Funds
